Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of Treatment-Emergent Adverse Events Time frame: Up to 100 Weeks. After: Measure: Incidence of Treatment-Emergent Adverse Events Time frame: Up to 248 Weeks.
Planned enrollment increased by 530 participants
Before: 256 participants (planned). After: 786 participants (planned).
Primary completion date changed
Before: Jun 2028. After: Jun 2030.